3DP Technology and life-saving drugs combine to deliver significant quality-of-life benefits for rare disease patients
13 December 2017 - CINCINNATI & CAMBRIDGE, England--(BUSINESS WIRE)
Aprecia Pharmaceuticals, The 3DP Pharmaceutical Company, and Cycle Pharmaceuticals today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose® Technology platform. ZipDose® is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration.
Antonio Benedetti, CEO of Cycle commented: “Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s ZipDose®3DP technology can formulate fast-melt pharmaceutical products, incorporating significantly higher amounts of active pharmaceutical ingredient than any other fast-melt technology on the market. As such, this advanced technology can uniquely overcome both pill burden and dysphagia – swallowing difficulties, both of which are life-long, daily issues for so many rare disease patients.”
“We are excited to work with the Cycle team, and we see important synergies in the companies’ shared mission to address unmet needs in patient care,” said Don Wetherhold, CEO of Aprecia. “Cycle specializes in orphan drugs - they have proven that they can deliver quality-of-life improvements to rare disease patients around the world. Aprecia is fully committed to applying its ZipDose® 3DP printing technology to address real-world, daily issues faced by rare disease patients,” he continued.
Source: Aprecia Pharmaceuticals, LLC
Illustration Photo: Drugs (CC0 Creative Commons from Pixabay.com)